How ketamine can quickly reverse stress-related loss of pleasure
Official title: A synaptic substrate for ketamine-mediated amelioration of stress-induced anhedonia
Funded at Washington University · NIH-11129906 · Data updated 2026-11-12
This work looks at how a single low dose of ketamine can rapidly restore pleasure and motivation for people with stress-related depression.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 15, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $388,750 |
| NIH project number | 5R01MH130610-04 |
| Project ID | NIH-11129906 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with major depressive disorder—especially those with treatment-resistant depression and prominent anhedonia—are the most relevant group for this line of research.
✕Less likely to help
People without depression or whose symptoms do not include loss of pleasure are unlikely to gain direct benefit from this specific research.
What this research studies
From a patient's perspective, researchers are examining the brain circuits and synapses that let ketamine relieve the loss of pleasure caused by chronic stress. They use laboratory models of stress-linked depression to see how ketamine activates AMPA receptors and promotes formation of new synaptic connections. The team measures behavior, images synapses, and manipulates specific neurons and receptors to map the precise steps involved. The aim is to identify targets that could lead to faster-acting treatments for people whose depression does not respond to standard antidepressants.
Why it matters
Potential benefit: If successful, this work could point to faster-acting antidepressant approaches that reduce anhedonia in people with treatment-resistant depression.
How similar studies have gone: Clinical trials have shown single low doses of ketamine can rapidly reduce depressive symptoms and anhedonia in many patients, but the detailed synaptic mechanisms remain incompletely tested.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Pignatelli, Marco — Washington University
- Study coordinator: Pignatelli, Marco
Related research
Other NIH-funded projects on the same topics.
-
Synaptic changes behind ketamine’s quick relief of stress-related anhedonia
Researchers are studying how a single low dose of ketamine rapidly eases anhedonia by changing brain connections, aiming to help people with treatment-resistant depression.
-
Ketamine's effects on anhedonia and anxiety in depression explored with ultra-high-field brain imaging
Researchers will study how specific brain circuits relate to anhedonia and anxiety in adults with depression using ultra-high-field MRI and ketamine-related insights.
-
Stress-related glutamate changes in the brain and ketamine for loss of pleasure
This work looks at whether stress changes a brain chemical called glutamate in people with depression and whether ketamine can help reverse loss of pleasure.
-
How stress affects brain chemistry and treatment response in depression
This study is looking at how long-term stress can make people lose interest in things they used to enjoy, which is a common issue for those with depression, and it aims to understand how changes in brain chemicals might explain this, so we can find better treatments for everyone affected.
-
Investigating how ketamine affects depression-related symptoms using advanced MRI technology
This study is looking at how ketamine helps people with depression feel better, especially when it comes to feeling joy and managing anxiety, by using advanced brain scans to see how certain parts of the brain work in adults with depression.
-
Investigating how stress affects reward response and treatment with ketamine
This study is looking at how long-term stress can make people with major depressive disorder lose interest in things they used to enjoy, and it aims to understand how a brain chemical called glutamate is involved, especially with the hope that ketamine might help improve these feelings.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.